Polishing of a Domain Antibody using Capto™ MMC ImpRes

Antibody fragments are becoming the latest group of molecules in monoclonal antibodies.

Several Fabs, single-chain Fv (scFv) and smaller molecules like domain antibodies (dAbs) are entering clinical trials at an accelerating rate. However the lack of an established platform makes the purification more challenging.

The recently introduced Capto™ L, a chromatography medium (resin) with Protein L as ligand, offers the possibility of building a platform based on affinity. Read more.

New Options for Capturing Different Antibody Fragments

Fabs and other antibody fragments are emerging as a significant group of engineered proteins in the biotherapeutic pipeline. Platform approaches to their production are just as smart as they have proven for monoclonal antibodies, but there is not such an obvious single candidate for affinity capture as Protein A has become for mAbs. However, several choices now exist for selective capture of different antibody fragments. Read more.